Dantrolene for the treatment of MDMA toxicity.
Brian E Grunau, Matthew O Wiens, Marc Greidanus
CJEM September 2010 DOI: 10.1017/s1481803500012653 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A 31-year-old man who took Ecstasy |
| Interventions | Dantrolene Mechanical ventilation |
| Topics | MDMA |
| Key findings | Administration of dantrolene, along with aggressive cooling and mechanical ventilation, resolved hyperthermia and rigidity in a patient with severe MDMA toxicity; rhabdomyolysis occurred but did not lead to renal failure, and the patient recovered fully. |
Abstract
MDMA (3,4-methylenedioxymethamphetamine), popularly known as “Ecstasy,” was first introduced and patented by Merck & Co., Inc., in 1914 as an appetite suppressant. Currently, its primary role is as an illegal stimulant used to produce a euphoric effect during parties. This case report de scribes a 31-year-old man who, after taking 3 tablets of Ecstasy, presented to an emergency department with a decreased level of consciousness and became progressively hyperthermic and rigid. During the course of his acute illness, his temperature reached 42.2°C rectally. He was given mechanical ventilation. He was aggressively cooled and dantrolene was initiated. Soon after the administration of dantrolene his temperature decreased and his rigidity began to resolve. The only complication was rhabdomyolysis with a creatine kinase level increasing to over 150 μkat/L. This did not progress to acute renal failure. The patient made a full recovery and was discharged to psychiatry for assessment.
Comparable studies
Other case reports and case series on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA Individuals whose deaths were associated with MDMA or MDEA use | 1987 | Case series | n = 5 |
| Pathology of deaths associated with "ecstasy" and "eve" misuse. Young white men aged 20 to 25 who died after using ring-substituted amphetamines (MDMA... | 1996 | Case series | n = 7 |
| 'Eve' and 'Ecstasy' Individuals who died after using MDMA or MDEA | 1987 | Case series | n = 5 |
| A Method of Conducting Therapeutic Sessions with MDMA Clients with clear therapeutic purpose, excluding those with serious functional... | 1998 | Case study | n = 2 |
| Diversity of Psychopathology Associated with use of 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) Psychiatric patients presenting between 1990 and 1992 whose symptoms developed in the... | 1994 | Case series | n = 13 |
Citations in the library
Cited by 3
- Caffeine and MDMA (ecstasy) exacerbate ER stress triggered by hyperthermia bioRxiv (Cold Spring Harbor Laboratory)
- MDMA toxicity: management of acute and life-threatening presentations. British journal of nursing June 14, 2018
- Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM September 2010
Cites 3
- Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM September 2010
- Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. British Journal of Anaesthesia June 2006
- An overdose of ecstasy. A role for dantrolene. Anaesthesia August 1992